Laure Farnault

Marseille, France

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 53 publications

Real-world patterns of treatment intensity and prognostic model performance in older acute myeloid leukemia: insights from the French ALFA-PPP Cohort.

Real-world patterns of treatment intensity and prognostic model performance in older acute myeloid leukemia: insights from the French ALFA-PPP Cohort.

Journal: Leukemia
Published: April 14, 2026

Blinatumomab consolidation for high-risk Ph- B-cell acute lymphoblastic leukemia: the GRAALL-2014/B-QUEST study.

Blinatumomab consolidation for high-risk Ph- B-cell acute lymphoblastic leukemia: the GRAALL-2014/B-QUEST study.

Journal: Blood
Published: January 20, 2026

Blinatumomab Consolidation for High-Risk Ph-negative B-cell Acute Lymphoblastic Leukemia: the GRAALL-2014/B-QUEST Study.

Blinatumomab Consolidation for High-Risk Ph-negative B-cell Acute Lymphoblastic Leukemia: the GRAALL-2014/B-QUEST Study.

Journal: Blood
Published: January 20, 2026

Sustained remission after discontinuation of ALK inhibition in ALK-positive histiocytosis.

Sustained remission after discontinuation of ALK inhibition in ALK-positive histiocytosis.

Journal: Blood cancer journal
Published: December 15, 2025

Comprehensive mutational profiling and clinical outcome of adult acute myeloid leukemia patients with NUP98 rearrangement.

Comprehensive mutational profiling and clinical outcome of adult acute myeloid leukemia patients with NUP98 rearrangement.

Journal: Leukemia
Published: August 25, 2025

Impact of CDA Dynamics on Clinical Outcome of Patients With AML or High-Risk MDS Treated With Nucleoside Analogs.

Impact of CDA Dynamics on Clinical Outcome of Patients With AML or High-Risk MDS Treated With Nucleoside Analogs.

Journal: Hematological oncology
Published: December 23, 2024

Predicting the toxicity-efficacy ratio of venetoclax in real-world patients.

Predicting the toxicity-efficacy ratio of venetoclax in real-world patients.

Journal: Annals of hematology
Published: December 09, 2024

Update on long-term outcomes of a cohort of patients with TCF3::HLF-positive acute lymphoblastic leukemia treated with blinatumomab and stem cell transplantation.

Update on long-term outcomes of a cohort of patients with TCF3::HLF-positive acute lymphoblastic leukemia treated with blinatumomab and stem cell transplantation.

Journal: Haematologica
Published: November 09, 2024

NPM1 mutation subtype switch in acute myeloid leukemia.

NPM1 mutation subtype switch in acute myeloid leukemia.

Journal: Haematologica
Published: November 06, 2024

Body mass index affects imatinib exposure: Real-world evidence from TDM with adaptive dosing.

Body mass index affects imatinib exposure: Real-world evidence from TDM with adaptive dosing.

Journal: Fundamental & clinical pharmacology
Published: July 24, 2024

Significance of Measurable Residual Disease in Adult Philadelphia Chromosome-Positive ALL: A GRAAPH-2014 Study.

Significance of Measurable Residual Disease in Adult Philadelphia Chromosome-Positive ALL: A GRAAPH-2014 Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 19, 2024

Clinical, biological, electrophysiological and therapeutic profile of patients with anti-MAG neuropathy according to MYD88L265P and CXCR4 mutations and underlying haemopathy.

Clinical, biological, electrophysiological and therapeutic profile of patients with anti-MAG neuropathy according to MYD88L265P and CXCR4 mutations and underlying haemopathy.

Journal: Journal of neurology
Published: July 26, 2023
Showing 1-12 of 53

Last Updated: 09/26/2026